HTT and juvenile Huntington disease: The antisense oligonucleotide HTT 90-5, designed to target the CAG repeat cluster in the Huntingtin gene, effectively reduced mutant Huntingtin expression in patient-derived primary leukocyte cultures without compromising cell viability, highlighting its potential as a therapeutic candidate for Huntington’s Disease.